Nicola Gathaiya, MD
Endocrinology, Diabetes & Metabolism · Springfield, MONPI 1154513752
Payments from drug & device makers
Across 242 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$673
- Sanofi-aventis U.S. LLC$521
- Novo Nordisk$453
- Amgen$443
- Lilly USA, LLC$336
- Boehringer Ingelheim$256
- plus $1K from 28 others
What the payments were for
- Food & beverage$4,063100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 39 | $673 |
| Sanofi-aventis U.S. LLC | 27 | $521 |
| Novo Nordisk | 34 | $453 |
| Amgen | 23 | $443 |
| Lilly USA, LLC | 21 | $336 |
| Boehringer Ingelheim | 20 | $256 |
| AstraZeneca | 6 | $139 |
| Insulet Corporation | 2 | $126 |
| Pfizer | 8 | $114 |
| Radius Health, Inc. | 4 | $113 |
| Dexcom, Inc. | 7 | $102 |
| AbbVie | 6 | $95 |
| Johnson & Johnson | 7 | $87 |
| Amarin Pharma, Inc. | 3 | $63 |
| Antares Pharma, Inc. | 4 | $58 |
| Corcept Therapeutics | 2 | $53 |
| Shire North American Group Inc | 4 | $46 |
| Merck | 3 | $43 |
| Averitas Pharma Inc. | 2 | $43 |
| Recordati_rare_diseases_inc. | 2 | $41 |
| Novartis | 3 | $41 |
| Medtronic | 2 | $30 |
| Aegerion Pharmaceuticals, Inc. | 2 | $24 |
| Intuity Medical Inc | 1 | $24 |
| Alvogen Inc | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| BETA Bionics, Inc. | 1 | $22 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Valeritas, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Cequr Corporation | 1 | $10 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,076 in reported general payments places this provider in the 60th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 130 | $149,514 |
| OzempicSemaglutide | 68 | $96,911 |
| TrulicityDulaglutide | 36 | $51,221 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $41,596 |
| JardianceEmpagliflozin | 21 | $34,557 |
| FarxigaDapagliflozin Propanediol | 15 | $23,290 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $22,400 |
| SynthroidLevothyroxine Sodium | 173 | $20,760 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 97 | $17,839 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $17,199 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $11,188 |
| Novolog FlexpenInsulin Aspart | 35 | $10,236 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 20 | $8,075 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 23 | $3,039 |
| Levothyroxine Sodium | 338 | $2,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $336 | $200,735166 claims |
| Novo NordiskOzempic | $453 | $96,91168 claims |
| Boehringer IngelheimJardiance | $256 | $34,55721 claims |
| AstraZenecaFarxiga | $139 | $23,29015 claims |
| AbbVieSynthroid | $95 | $20,760173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Springfield
- Ralph DudaSpringfield$3M
- Gregory LedgerSpringfield$690K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Christopher CaseJefferson City$692K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.